Research License Sample Clauses

Research License. Each Collaborator shall allow the other Collaborator to practice any of its Non- Subject Inventions for the purpose of performing the Cooperative Work. No license, express or implied, for commercial application(s) is granted to either Collaborator in Non-Subject Inventions by performing the Cooperative Work. For commercial application(s) of Non-Subject Inventions, a license must be obtained from the owner.
AutoNDA by SimpleDocs
Research License. Following Selection of each CGI Antigen (or exercise of a Buy-In Right for each CGI Antigen) and subject to the terms and conditions of this Agreement, ABX agrees to grant, and hereby grants, to CGI a nonexclusive sublicense under the Licensed Technology to develop, make, have made, use, import or export or otherwise transfer physical possession of (but not to sell, lease, offer to sell or lease, or otherwise transfer title to) Covered Products related to such CGI Antigen and cells that express or secrete Antibodies to such CGI Antigen, in each case solely for purposes relating to or in connection with research or development (i) of Covered Products for use in the field of Gene Therapy or (ii) involving Genetic Material when used with viral or nonviral gene transfer systems. CGI shall have the right to sublicense the rights granted under this Section 2.5 upon the approval of ABX, which approval shall not be unreasonably withheld. In the event that ABX refuses to approve such a sublicense, ABX shall, to the extent that ABX has the right to do so, grant at CGI's request a nonexclusive sublicense of such rights directly to a non-Affiliate third party designated by CGI on terms and conditions substantially identical to the applicable terms and conditions of this Agreement. The sublicense granted by ABX under this Section 2.5 with respect to a CGI Antigen (and the further sublicenses, if any, granted by CGI under this Section 2.5 with respect to such CGI Antigen) shall terminate at such time as (A) CGI sends ABX an Abandonment Notice pursuant to Section 2.4.1 above regarding such CGI Antigen or (B) CGI enters into a CGI Product Sublicense related to such CGI Antigen; provided, however, that termination of a sublicense under this Section 2.5 with respect to a CGI Antigen pursuant to (B) above shall not affect the duration or survival of a grant of similar rights or sublicense under the CGI Product Sublicense with respect to such CGI Antigen, which rights or sublicense shall terminate or expire only in accordance with the terms of such CGI Product Sublicense. In the event that ABX enters into a Product Sublicense with respect to a CGI Antigen and CGI has not within six (6) months thereafter entered into a CGI Product Sublicense with respect to such CGI Antigen, the sublicense granted under this Section 2.5 with respect to such CGI Antigen shall terminate. It is understood and agreed that (x) as to ABX-Controlled Rights, the grant of rights under this Section 2.5 ...
Research License. During the term of the Development Program, Medicis hereby grants to Impax a fully paid, non-exclusive, non-transferable (except as permitted in Section 11.6) license (without the right to grant sublicenses), under all patents, know-how and other intellectual property rights Controlled by Medicis, for the sole purpose of conducting the Development Program. Prior to engaging any subcontractors to perform work under the Development Program, Impax shall notify Medicis in writing of the names and addresses of the subcontractors so that Medicis may screen such subcontractors against the Exclusion Lists and any other legal requirements. If, within fourteen (14) days following submission of the list to Medicis, Medicis does not object to the use of such subcontractors on the basis that such subcontractors fail to comply with the foregoing requirements or the representations under Section 9.2, Impax may proceed with use of such subcontractors. The foregoing shall not relieve Impax of its requirements under Section 9.2.
Research License. Subject to the terms of this Agreement, Genentech hereby: (i) grants to Curis a non-exclusive, worldwide, royalty-free license during the Term, [**], under the Genentech Technology, to perform Curis’ obligations under the Research Plan; and (ii) grants back to Curis a non-exclusive, worldwide, royalty-free license during the Term, [**], under the rights licensed to Genentech under Section 7.1(a), to perform Curis’ obligations under the Research Plan.
Research License. Ablynx hereby grants to Merck a fully paid-up, perpetual, irrevocable, non-exclusive license under all Program Know-How Controlled by Ablynx (or any of its Affiliates) at any time during the Term, solely for research purposes. In addition, Ablynx hereby grants to Merck a fully paid-up, perpetual, irrevocable, non-exclusive license under the Ablynx Know-How Controlled by Ablynx and Ablynx Patent Rights Controlled by Ablynx in order for Merck to use or otherwise exploit Program Know-How for research purposes. For clarity, the foregoing licenses shall not limit in any way the exclusive licenses granted to Merck under Section 3.1.1. The licenses set forth in this Section 3.1.4 shall survive the expiration or termination of this Agreement. For clarity, in respect of Ablynx Know-How (other than Program Know-How) licensed to Merck pursuant to this Section 3.1.4, the license granted to Merck under this Section 3.1.4 shall only apply to the extent that such Ablynx Know-How is reasonably necessary in order to use the Program Know-How for research purposes.
Research License. Subject to the terms and conditions of this Agreement, BMS hereby grants back to CytomX a limited, non-exclusive, non-sublicensable, royalty-free license BMS intellectual property rights covering the BMS Information or Materials provided to CytomX and any Sole Inventions owned by BMS, solely to conduct the Preclinical Development Program, and not for any other purpose.
Research License. Subject to the terms and conditions of this Agreement, including without limitation, the restrictions set forth in Section 3.2 and the payment obligations set forth in Article 4, Dyax hereby grants to Merrimack and its Affiliates a world-wide, non-exclusive, royalty-free, non-transferable license, without the right to sublicense, under the Dyax Patent Rights, Dyax Research Know-How, Dyax Antibody Information, Dyax Antibody IP, and CAT Patent Rights to use Dyax Research Materials and to research, develop and make Dyax Antibodies, solely in the Research Field.
Research License. (a) Rigel grants Pfizer an irrevocable, nonexclusive, worldwide license under its interest in Program Technology, except Rigel Core Technology, and under all intangible technology, technical information, know-how, expertise and trade secrets within Rigel Technology disclosed to Pfizer during the course of the Research Program, solely for the purpose of conducting research.
Research License. Subject to the terms of this Agreement, HMI hereby grants to NVS and its Affiliates, (a) during the Research Term, a worldwide, non-exclusive research license, with the right to grant sublicenses through multiple tiers in accordance with Section 4.3 (Sublicensing Rights), under the HMI Licensed Technology solely to perform its responsibilities under any Research Plan; (b) a worldwide license, with the right to grant sublicenses through multiple tiers in accordance with Section 4.3 (Sublicensing Rights), under the HMI Licensed Technology to conduct Preclinical Development activities with respect to Candidates and Products (including the use of Target Reagents), which license will be (i) co-exclusive (with HMI) during the Research Term; and (ii) exclusive during the remainder of the Term; and (c) a worldwide, non-exclusive, perpetual, irrevocable license, without the right to grant sublicenses, to use Exploratory Reagents and Target Reagents, and any improvements, modifications, or derivatives resulting from the use thereof, solely for its internal research purposes ((a) – (c) together the “Research License”).
Time is Money Join Law Insider Premium to draft better contracts faster.